Showing 2,481 - 2,500 results of 3,304 for search '"clinical trials"', query time: 0.08s Refine Results
  1. 2481

    Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti... by Arndt Borkhardt, Nan Qin, Stephen T Keir, Darell D Bigner, Allison Cole, Matthias Wölfl, Viktoria Marquardt, Johanna Theruvath, David Pauck, Daniel Picard, Lena Blümel, Mara Maue, Jasmin Bartl, Ulvi Ahmadov, Maike Langini, Frauke-Dorothee Meyer, Joselyn Cruz-Cruz, Claus M Graef, Till Milde, Olaf Witt, Anat Erdreich-Epstein, Gabriel Leprivier, Ulf Kahlert, Anja Stefanski, Kai Stühler, Julia Hauer, Thomas Beez, Christiane B Knobbe-Thomsen, Ute Fischer, Jörg Felsberg, Finn K Hansen, Rajeev Vibhakar, Sujatha Venkatraman, Samuel H Cheshier, Guido Reifenberger, Thomas Kurz, Marc Remke, Siddhartha Mitra

    Published 2023-01-01
    “…Therefore, targeting epigenetic modifiers for cancer treatment has gained increasing interest, and inhibitors for various epigenetic modulators have been intensively studied in clinical trials. Here, we report a cross-entity, epigenetic drug screen to evaluate therapeutic vulnerabilities in MYC amplified MB, which sensitizes them to macrophage-mediated phagocytosis by targeting the CD47-signal regulatory protein α (SIRPα) innate checkpoint pathway.Methods We performed a primary screen including 78 epigenetic inhibitors and a secondary screen including 20 histone deacetylase inhibitors (HDACi) to compare response profiles in atypical teratoid/rhabdoid tumor (AT/RT, n=11), MB (n=14), and glioblastoma (n=14). …”
    Get full text
    Article
  2. 2482
  3. 2483
  4. 2484

    Surgical interventions for spontaneous supratentorial intracerebral haemorrhage: a systematic review and network meta-analysisResearch in context by Jiayidaer Huan, Minghong Yao, Yu Ma, Fan Mei, Yanmei Liu, Lu Ma, Xiaochao Luo, Jiali Liu, Jianguo Xu, Chao You, Hunong Xiang, Kang Zou, Xiao Liang, Xin Hu, Ling Li, Xin Sun

    Published 2025-01-01
    “…Methods: In this systematic review and network meta-analysis, we searched PubMed, Cochrane Central Register of Controlled Trials, Embase, and ClinicalTrials.gov from inception to June 16, 2024. Eligible studies were randomised controlled trials (RCTs) comparing surgery (i.e., CC, ES, MIPS, or DC) with CMT or comparing different types of surgeries in patients with spontaneous supratentorial ICH. …”
    Get full text
    Article
  5. 2485

    Multi-cancer early detection tests for general population screening: a systematic literature review by Ros Wade, Sarah Nevitt, Yiwen Liu, Melissa Harden, Claire Khouja, Gary Raine, Rachel Churchill, Sofia Dias

    Published 2025-01-01
    “…Published and unpublished prospective clinical trials and cohort studies of blood-based MCED tests for screening were sought. …”
    Get full text
    Article
  6. 2486
  7. 2487
  8. 2488

    Combined pyrotinib and fulvestrant for hormone receptor‐positive and HER2‐positive metastatic breast cancer: A multicenter, single‐arm, phase II trial by Jianli Zhao, Yunfang Yu, Wei Ren, Linxiaoxiao Ding, Yongjian Chen, Peng Yuan, Jian Yue, Yaping Yang, Guorong Zou, Tao Chen, Jie Chai, Li Zhang, Wenjing Wu, Yinduo Zeng, Xiujuan Gui, Yangyang Cai, Simin Luo, Zhongyu Yuan, Kang Zhang, Herui Yao, Ying Wang

    Published 2025-01-01
    “…Abstract This multicenter, single‐arm, phase II clinical trial (NCT04034589) evaluated the efficacy and safety of pyrotinib combined with fulvestrant in patients with HR‐positive/HER2‐positive metastatic breast cancer who had experienced trastuzumab treatment failure. …”
    Get full text
    Article
  9. 2489
  10. 2490
  11. 2491
  12. 2492
  13. 2493
  14. 2494

    A Profile of Patients on ASA or NSAIDs Hospitalized with Gastrointestinal Perforations by James D Bailey, Robert J Bailey, Richard N Fedorak

    Published 1995-01-01
    “…BACKGROUND: In a recent clinical trial gastrointestinal tract perforations in patients on nonsteroidal anti-inflammatory drugs (NSAIDs) were found to occur with a frequency of 0.15%, and possibly to be reduced in patients concomitantly using the cytoprotective agent misoprostol.…”
    Get full text
    Article
  15. 2495
  16. 2496
  17. 2497

    A prospective pragmatic evaluation of automatic trial matching tools in a molecular tumor board by Lilia Gueguen, Louise Olgiati, Clément Brutti-Mairesse, Alric Sans, Vincent Le Texier, Loic Verlingue

    Published 2025-01-01
    “…During 10 weeks in 2024, we analysed 157 patients with four clinical trial matching tools from the 19 screened: Klineo, ScreenAct, Trialing and DigitalECMT. …”
    Get full text
    Article
  18. 2498

    New Antibody Conjugates in Cancer Therapy by Serengulam V. Govindan, David M. Goldenberg

    Published 2010-01-01
    “…Radioimmunotherapy (RAIT) of lymphoma using directly labeled MAbs is of current interest after approval of two radiolabeled anti-CD20 MAbs, as illustrated with the near 100% overall response rate obtained in a recent clinical trial using an investigational radiolabeled anti-CD22 MAb, 90Y-epratuzumab. …”
    Get full text
    Article
  19. 2499

    Evaluation of undergraduate dental students’ awareness, knowledge, and attitudes towards teledentistry: does a course enhance this? by Gökçen Akçiçek, Ezgi Katı, Hatice Yağmur Zengin

    Published 2025-01-01
    “…Conclusions Enhancing dental students’ knowledge and awareness of teledentistry could beneficially influence their utilization of teledentistry in their future careers. Clinical trial number This study is not a clinical trial involving medicinal products or therapeutic interventions, so the clinical trial number is not applicable.…”
    Get full text
    Article
  20. 2500